XENE vs ZYME Stock Comparison
ZYME currently leads XENE in this stock comparison, with AIQ scores of 68 vs 49. The clearest difference is momentum, while XENE has the stronger quality profile.
What is the main difference between XENE and ZYME?
ZYME leads the current stock comparison as Zymeworks Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Xenon Pharmaceuticals Inc. vs Zymeworks Inc.
ZYME leads
ZYME leads by 19 AIQ points, primarily on Momentum and Risk Resilience, and the lead has widened from 5 points over 30 sessions. Wall Street currently favors XENE on target upside.
Stable: 4 of 5 evidence groups support ZYME, its lead is widening, and its current signal state is conflicted.
Xenon Pharmaceuticals Inc.
Zymeworks Inc.
The Algovestiq AIQ Score currently favors ZYME over XENE, 68 versus 49 as of Nov 15, 2026. ZYME's advantage is driven primarily by stronger momentum and risk resilience, while XENE holds the stronger quality profile. ZYME also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors XENE. 4 of 5 covered evidence groups favor ZYME today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. ZYME lead: Strengthening — the AIQ differential moved from 5 to 19 points over 30 sessions.
Compare Xenon Pharmaceuticals Inc. and Zymeworks Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare XENE and ZYME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum33 vs 78ZYME +45
- Risk Resilience49 vs 61ZYME +12
- Quality68 vs 62XENE +6
4 of 5 evidence groups favor ZYME. ZYME’s edge is concentrated in momentum and risk resilience; XENE keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.47x)
Largest factor move: Risk Resilience +4
New signals
- Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
ZYME's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — XENE and ZYME both carry a full feed there.
The central trade-off
ZYME (Zymeworks Inc.): the stronger current systematic profile, led by momentum and risk resilience.
XENE (Xenon Pharmaceuticals Inc.): the counter-case, on quality, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ZYMEZYME on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ZYMEZYME on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
ZYMEZYME on the Momentum factor, by 45 points.
Lower downside
ZYMEZYME on Risk Resilience, by 12 points.
Analyst upside
XENEXENE on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors ZYME, analyst targets favor XENE. That disagreement is the most useful thing on this page.
| Measure | XENE | ZYME | Note |
|---|---|---|---|
| Implied upside to target | +67.6% | +62.3% | XENE has more room |
| Target dispersion | +64.8% | +54% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 18 | 14 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 5 covered evidence groups favor ZYME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ZYME | 49 vs 68 |
| Fundamentals | ZYME | TTM ROE -9.6% vs 67.3% |
| Valuation | Not covered | Not covered |
| Technicals | ZYME | Price vs 50-day -1.6% vs -4%; vs 200-day -22.6% vs 2.8% |
| Risk Resilience | ZYME | Risk Resilience 49 vs 61 |
| Analyst expectations | XENE | Target upside 67.6% vs 62.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of XENE and ZYME and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 19 points. (supports the conclusion holding)
- 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ZYME.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ZYME lead: Strengthening — the AIQ differential moved from 5 to 19 points over 30 sessions.
- Today
- ZYME +19
- 49 vs 68
- 7 sessions ago
- ZYME +10
- 49 vs 59
- 30 sessions ago
- ZYME +5
- 46 vs 51
- 90 sessions ago
- XENE +23
- 73 vs 50
The lead changed hands once in this window, most recently on Sep 25 when ZYME moved ahead of XENE.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 2 neutral
Only XENE
- Death Cross Active — bearish, trend, long horizon (27.10%)
- Downtrend Structure Active — bearish, trend, long horizon
2 bullish / 2 bearish / 2 neutral, conflicted
Only ZYME
- Golden Cross Active — bullish, trend, long horizon (7.04%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
Both carry 3 more signals that do not separate them: ADX Trend Weakening, ATR Expansion - Breakout Mode, Low Volume Rally Warning.
ZYME leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -1.26%, AIQ 0 points).
Price is down while the AIQ Score moved up 2 points over the same session — price and model disagree (price -0.87%, AIQ +2 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1XENE closes the Momentum gap — currently 45 points behind, the largest single contributor to ZYME's edge.
- 2XENE's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ZYME leads on balance| Metric | XENE | ZYME |
|---|---|---|
| Revenue growth (YoY) | 0% | 54.9% |
| EPS growth (YoY) | 0% | 4.9% |
| Gross margin | 0% | 98.3% |
| Operating margin | 0% | 16.6% |
| Return on equity (TTM) | -9.6% | 67.3% |
| Debt to equity | 0.01 | 2.52 |
Performance
ZYME leads 4 of 6 windows| Metric | XENE | ZYME |
|---|---|---|
| 1 week (5 sessions) | 3.3% | -11.4% |
| 1 month (20 sessions) | 20.9% | 4.8% |
| 3 months (63 sessions) | -35.1% | 3.7% |
| 6 months (126 sessions) | -25.6% | 9.7% |
| Year to date | -9.7% | -0.3% |
| 1 year (252 sessions) | 2% | 35.5% |
Technicals
ZYME has the stronger structure| Metric | XENE | ZYME |
|---|---|---|
| RSI (14) | 54.9 | 42 |
| ADX (14) | 24 | 23.8 |
| Price vs 50-day | -1.6% | -4% |
| Price vs 200-day | -22.6% | 2.8% |
| Volatility (1M, annualized) | 38% | 63.1% |
Risk
ZYME is the more resilient| Metric | XENE | ZYME |
|---|---|---|
| Beta | 0.86 | 0.78 |
| Sharpe ratio | 0.27 | 0.84 |
| Sortino ratio | 0.48 | 1.39 |
| Max drawdown | -52.8% | -23.6% |
| Current drawdown | -43% | -16.6% |
| Annualized volatility | 68.1% | 54% |
| Value at risk (95%) | -3.3% | -4.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, XENE or ZYME?
On the Algovestiq AIQ Score, ZYME is the stronger of the two as of Nov 15, 2026, scoring 68 against XENE's 49. The edge comes from momentum and risk resilience. XENE is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is XENE or ZYME the better buy right now?
ZYME carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ZYME over XENE?
The composite weights Quality, Value, Momentum and Risk Resilience. ZYME leads Momentum by 45 points; ZYME leads Risk Resilience by 12 points; XENE leads Quality by 6 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, XENE or ZYME?
Analyst price targets imply +67.6% upside for XENE and +62.3% for ZYME, so the Street currently favors XENE. That points the opposite way to the AIQ Score, which favors ZYME. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, XENE or ZYME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, XENE or ZYME?
ZYME on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, XENE or ZYME?
ZYME on the Momentum factor, by 45 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, XENE or ZYME?
ZYME is the more resilient of the two, so the other name carries the higher downside risk. ZYME on Risk Resilience, by 12 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is XENE more profitable than ZYME?
ZYME leads on the comparable margin measures — gross margin 0% vs 98.3%; operating margin 0% vs 16.6%; ttm roe -9.6% vs 67.3%.
Is ZYME's lead over XENE getting stronger or weaker?
ZYME lead: Strengthening — the AIQ differential moved from 5 to 19 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-09-25, when ZYME moved ahead of XENE.
What would change the XENE vs ZYME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: XENE closes the Momentum gap — currently 45 points behind, the largest single contributor to ZYME's edge; XENE's Death Cross Active resolves — a bearish trend rule currently active against it; ZYME's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about XENE and ZYME?
XENE: 0 bullish / 3 bearish / 2 neutral. ZYME: 2 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on XENE is Death Cross Active (bearish, long horizon). On ZYME it is Golden Cross Active (bullish, long horizon).
Compare XENE and ZYME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.